BIOMARKED is the Ghent University business unit assisting researchers in translation of pre-clinical translational biomarker research towards opportunities for Pharma/Biotech companies in developing diagnostics and targeted therapies in the field of oncology, HIV and ageing diseases. Specific focus of BIOMARKED is on the most innovative technology platforms for the identification, validation of novel and more accurate biomarkers for risk stratification, early diagnosis and prediction of therapy, development of RNA based therapies, bioinformatic pipelines and databases, new diagnostic methods and pre-clinical validation models and development of biologics for eye diseases.

BIOMARKED activities focus on scouting/protection of valorisation opportunities, de-risking diagnostic and early targeted therapy projects, networking towards stronger collaboration between pharma/biotech companies and UGent, facilitation of bilateral collaborations, licensing and setting up spinouts.